Free Trial

Everett Harris & Co. CA Acquires 11,507 Shares of Merck & Co., Inc. (NYSE:MRK)

Merck & Co., Inc. logo with Medical background

Key Points

  • Everett Harris & Co. CA boosted its stake in Merck & Co., Inc. by 5.8%, acquiring 11,507 shares to bring its total holdings to 210,775 shares, valued at approximately $18.9 million.
  • Merck's recent quarterly earnings reported an EPS of $2.13, exceeding analyst expectations, despite revenue of $15.81 billion, which was below the projected $15.92 billion.
  • The company announced a quarterly dividend of $0.81 per share, resulting in an annualized dividend yield of 4.0% for shareholders.
  • Looking to Export and Analyze Merck & Co., Inc. Data? Unlock 5 Weeks of MarketBeat All Access for Just $5. Claim Your Limited-Time Discount.

Everett Harris & Co. CA lifted its position in shares of Merck & Co., Inc. (NYSE:MRK - Free Report) by 5.8% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 210,775 shares of the company's stock after buying an additional 11,507 shares during the quarter. Everett Harris & Co. CA's holdings in Merck & Co., Inc. were worth $18,919,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also made changes to their positions in MRK. Barnes Dennig Private Wealth Management LLC acquired a new position in shares of Merck & Co., Inc. during the 1st quarter valued at about $27,000. MorganRosel Wealth Management LLC purchased a new position in Merck & Co., Inc. in the 1st quarter worth approximately $36,000. Spurstone Advisory Services LLC purchased a new position in Merck & Co., Inc. in the fourth quarter valued at about $37,000. Marshall & Sterling Wealth Advisors Inc. acquired a new stake in shares of Merck & Co., Inc. during the fourth quarter worth approximately $44,000. Finally, Minot DeBlois Advisors LLC acquired a new position in Merck & Co., Inc. during the 4th quarter worth $45,000. Institutional investors and hedge funds own 76.07% of the company's stock.

Wall Street Analysts Forecast Growth

Several equities research analysts recently issued reports on the company. Citigroup reissued a "neutral" rating and set a $84.00 price target (down from $115.00) on shares of Merck & Co., Inc. in a research report on Wednesday, May 14th. Cantor Fitzgerald lowered shares of Merck & Co., Inc. from an "overweight" rating to a "cautious" rating in a research note on Tuesday, May 20th. Wells Fargo & Company lowered their target price on shares of Merck & Co., Inc. from $97.00 to $90.00 and set an "equal weight" rating for the company in a research note on Wednesday, July 30th. Wall Street Zen lowered shares of Merck & Co., Inc. from a "strong-buy" rating to a "buy" rating in a research note on Friday, April 25th. Finally, Guggenheim reiterated a "buy" rating and set a $115.00 target price on shares of Merck & Co., Inc. in a research note on Thursday, April 17th. One analyst has rated the stock with a sell rating, twelve have issued a hold rating, seven have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of "Hold" and an average target price of $107.44.

View Our Latest Stock Report on Merck & Co., Inc.

Merck & Co., Inc. Price Performance

MRK stock traded up $0.36 during trading on Friday, hitting $80.73. The company had a trading volume of 6,882,063 shares, compared to its average volume of 12,387,496. The firm has a market capitalization of $201.65 billion, a price-to-earnings ratio of 12.44, a P/E/G ratio of 0.85 and a beta of 0.38. The business has a 50 day moving average of $80.74 and a 200 day moving average of $83.94. Merck & Co., Inc. has a fifty-two week low of $73.31 and a fifty-two week high of $120.30. The company has a current ratio of 1.42, a quick ratio of 1.16 and a debt-to-equity ratio of 0.69.

Merck & Co., Inc. (NYSE:MRK - Get Free Report) last issued its quarterly earnings results on Tuesday, July 29th. The company reported $2.13 earnings per share for the quarter, beating analysts' consensus estimates of $2.03 by $0.10. Merck & Co., Inc. had a net margin of 25.79% and a return on equity of 41.05%. The company had revenue of $15.81 billion during the quarter, compared to the consensus estimate of $15.92 billion. As a group, research analysts predict that Merck & Co., Inc. will post 9.01 earnings per share for the current year.

Merck & Co., Inc. Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, October 7th. Shareholders of record on Monday, September 15th will be paid a dividend of $0.81 per share. The ex-dividend date of this dividend is Monday, September 15th. This represents a $3.24 dividend on an annualized basis and a yield of 4.0%. Merck & Co., Inc.'s dividend payout ratio is currently 49.92%.

Merck & Co., Inc. Company Profile

(Free Report)

Merck & Co, Inc is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products.

Read More

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Should You Invest $1,000 in Merck & Co., Inc. Right Now?

Before you consider Merck & Co., Inc., you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Merck & Co., Inc. wasn't on the list.

While Merck & Co., Inc. currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 AI Stocks to Invest in Today: Capitalizing on AI and Tech Trends in 2025 Cover

Discover the top 7 AI stocks to invest in right now. This exclusive report highlights the companies leading the AI revolution and shaping the future of technology in 2025.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

3 Growth Stocks That Could Pop Before Summer Ends
3 Buy-the-Dip Stocks Poised to Rebound Soon
Quantum Boom: 3 Strong Picks with Lower Risk

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines